

Web references

1. Sherman DG, Hart RG, Easton JD. The secondary prevention of stroke in patients with atrial fibrillation. *Arch Neurol* 1986;**43**(1):68–70.
2. Goldman ME, Pearce LA, Hart RG, *et al.* Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study). *J Am Soc Echocardiogr* 1999;**12**(12):1080–7.
3. Crystal EA, Lamy SJ, Connolly P, *et al.* Left Atrial Appendage Occlusion Study (LAAOS): A randomized clinical trial of left atrial appendage occlusion during routine coronary artery bypass graft surgery for long-term stroke prevention. *Am Heart J* 2003;**145**(1):174–8.
4. Weinberger J, Rothlauf E, Materese E, *et al.* Noninvasive evaluation of the extracranial carotid arteries in patients with cerebrovascular events and atrial fibrillations. *Arch Intern Med* 1988;**148**(8):1785–8.
5. Kamiyama N, Koyama Y, Saito Y, *et al.* Pulse dispersion due to atrial fibrillation causes arterial thrombosis in a rabbit experimental model. *Jpn Circ J* 2000;**64**(7):516–9.
6. Levy S, Breithardt G, Campbell RW, *et al.* Atrial fibrillation: current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology. *Eur Heart J* 1998;**19**(9):1294–320.
7. Sievert H, Lesh MD, Trepels T, *et al.* Percutaneous Left Atrial Appendage Transcatheter Occlusion to Prevent Stroke in High-Risk Patients With Atrial Fibrillation: Early Clinical Experience. *Circulation* 2002;**105**(16):1887–1889.

8. Harris D, Leor J, Assaf Y, *et al.* Convergence and Stabilization of Cellular Proliferation Into Steady State Over the Permanent Arterial Filtration Struts of the Diverter: A Novel Percutaneous Device for Protection Against Embolic Stroke. Abstract. *J Am Coll Card* 2003;**41**:300–301A.
9. Oral anticoagulant therapy. In Hoffman: Hematology: Basic Principles and Practice, 2000, Churchill Livingstone, Inc.
10. Hylek EM, Skates SJ, Sheehan MA, *et al.* An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. *N Engl J Med* 1996;**335**(8):540–6.
11. Benavente O, Hart R, Koudstaal P, *et al.* Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks (Cochrane Review). In: The Cochrane Library, Issue 1 2003. Oxford: Update Software, 2003.
12. Koudstaal PJ. Antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks (Cochrane Review). In: The Cochrane Library, Issue 1 2003. Oxford: Update Software, 2003.
13. Taylor FC, Cohen H, Ebrahim S. Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. *Bmj* 2001;**322**(7282):321–6.
14. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. *Ann Intern Med* 1994;**120**(11):897–902.

15. Fihn SD, Callahan CM, Martin DC, *et al.* The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. *Ann Intern Med* 1996;**124**(11):970–9.
16. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. *Am J Med* 1989;**87**(2):144–52.
17. Stafford RS, Singer DE. National patterns of warfarin use in atrial fibrillation. *Arch Intern Med* 1996;**156**(22):2537–41.
18. Bungard TJ, Ghali WA, Teo KK, *et al.* Why do patients with atrial fibrillation not receive warfarin? *Arch Intern Med* 2000;**160**(1):41–6.
19. Cohen N, Almozni-Sarafian D, Alon I, *et al.* Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. *Stroke* 2000;**31**(6):1217–22.
20. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. *Arch Intern Med* 1998;**158**(15):1641–7.
21. Cromheecke ME, Levi M, Colly LP, *et al.* Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. *Lancet* 2000;**356**(9224):97–102.
22. Albers GW, Dalen JE, Laupacis A, *et al.* Antithrombotic therapy in atrial fibrillation. *Chest* 2001;**119**(1 Suppl):194S–206S.
23. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. *Arch Intern Med* 1994;**154**(13):1449–57.